ID   IMR/KAT100
AC   CVCL_A8UT
DR   cancercelllines; CVCL_A8UT
DR   IARC_TP53; 26505
DR   Wikidata; Q108820545
RX   PubMed=17974978;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_2761; Dipotassium bis[mu-tartrato(4-)]diantimonate(2-) trihydrate (Antimony potassium tartrate; KAT).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Homozygous (PubMed=17974978).
CC   Derived from site: Metastatic; Abdomen; UBERON=UBERON_0000916.
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0346 ! IMR-32
SX   Male
AG   1Y1M
CA   Cancer cell line
DT   Created: 23-09-21; Last updated: 19-12-24; Version: 6
//
RX   PubMed=17974978; DOI=10.1158/0008-5472.CAN-06-4345;
RA   Xue, Cheng-Yuan
RA   Haber, Michelle
RA   Flemming, Claudia
RA   Marshall, Glenn Mark
RA   Lock, Richard B.
RA   MacKenzie, Karen L.
RA   Gurova, Katerina V.
RA   Norris, Murray D.
RA   Gudkov, Andrei V.
RT   "p53 determines multidrug sensitivity of childhood neuroblastoma.";
RL   Cancer Res. 67:10351-10360(2007).
//